Osteoimmunology: The study of the relationship between the immune system and bone tissue;Osteoinmunología: El estudio de la relación entre el sistema inmune y el tejido óseo

Reumatologia Clinica

Volumn 9, Issue 5, 2013, Pages 303-315

  Arboleya, Luis ^a   Castañeda, Santos ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Bone cells; Bone tissue; Immune system; Lymphocytes; Osteoimmunology; Osteoporosis; Rheumatoid arthritis

Indexed keywords

BONE CELL; BONE TISSUE; HEMATOPOIESIS; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; OSTEOIMMUNOLOGY; POSTMENOPAUSE OSTEOPOROSIS; SHORT SURVEY;

ARTRITIS REUMATOIDE; BONE CELLS; BONE TISSUE; CÉLULAS ÓSEAS; IMMUNE SYSTEM; LINFOCITOS; LYMPHOCYTES; OSTEOIMMUNOLOGY; OSTEOINMUNOLOGÍA; OSTEOPOROSIS; RHEUMATOID ARTHRITIS; SISTEMA INMUNE; TEJIDO ÓSEO;

ALLERGY AND IMMUNOLOGY; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE DISEASES; BONE REMODELING; HUMANS; IMMUNE SYSTEM; MEDICINE; OSTEOCLASTS; OSTEOCYTES; OSTEOLOGY; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND;

EID: 84881376837     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2013.02.008     Document Type: Short Survey

References (95)

1. Wigley C. Functional anatomy of the musculoskeletal system. Gray's Anatomy 2008, 81-136. Elsevier, New York. 40a ed. S. Standring (Ed.).
2. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol 2008, 3:S131-S139.
3. Harel Z. Bone metabolism during adolescence: the known, the unknown, and the controversial. Adolesc Med State Art Rev 2008, 19:573-591.
4. Seeman E. Modelling and remodelling. Principles of bone biology 2008, 3-28. Elsevier Inc, St. Louis, cap. 1. 3a ed. J. Bilezikian, L.G. Raisz, T.J. Martin (Eds.).
5. Arron J.R., Choi Y. Bone versus immune system. Nature 2000, 408:535-536.
6. Osteoimmunology 2011, Academic Press, Elsevier Inc, London. J. Lorenzo, Y. Choi, M. Horowitz, H. Takayanagi (Eds.).
7. Geusens P., Lems W.F. Osteoimmunology and osteoporosis. Arth Res Ther 2011, 13:242-258.
8. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
9. Monroe D.G., McGee-Lawrence M., Oursler M.J., Westendorf J.J. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012, 492:1-18.
10. Feng X., McDonald J.M. Disorders of bone remodeling. Annu Rev Pathol 2011, 6:121-145.
11. Kular J., Tickner J., Chim S.M., Xuet J. An overview of the regulation of bone remodelling at the cellular level. Clin Biochem 2012, 45:863-873.
12. + antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 2008, 453:788-792.
13. Kornak U., Kasper D., Bösl M.R., Kaiser E., Schweizer M., Schulz A., et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001, 104:205-215.
14. Schaller S., Henriksen K., Sveigaard C., Heegaard A.M., Hélix N., Stahlhut M., et al. The chloride channel inhibitor NS3736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004, 19:1144-1153.
15. Kasper D., Planells-Cases R., Fuhrmann J.C., Scheel O., Zeitz O., Ruether K., et al. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 2005, 24:1079-1091.
16. Asagiri M., Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264.
17. Barrow A.D., Raynal N., Andersen T.L., Slatter D.A., Bihan D., Pugh N., et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest 2011, 121:3505-3516.
18. Otero K., Shinohara M., Zhao H., Cella M., Gilfillan S., Colucci A., et al. TREM-2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol 2012, 188:2612-2621.
19. Marie P., Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol 2011, 165:1-10.
20. Baek W.Y., Kim J.E. Transcriptional regulation of bone formation. Front Biosci 2011, 3:126-135.
21. Chen G., Deng C., Li Y.P. TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012, 8:272-288.
22. Higashi Y., Sukhanov S., Anwar A., Shai S.Y., Delafontaine P. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci 2012, 67:626-639.
23. Franz-Odendaal T.A., Hall B.K., Witten P.E. Buried alive: how osteoblasts become osteocytes. Dev Dyn 2006, 235:176-190.
24. Batra N., Kar R., Jiang J.X. Gap junctions and hemichannels in signal transmission, function and development of bone. Biochim Biophys Acta 2012, 1818:1909-1918.
25. Atkins G.J., Findlay D.M. Osteocyte regulation of bone mineral: a little give and take. Osteoporos Int 2012, 23:2067-2079.
26. Neve A., Corrado A., Cantatore F.P. Osteocytes: central conductors of bone biology in normal and pathological conditions. Acta Physiol (Oxf) 2012, 204:317-330.
27. Galli C., Passeri G., Macaluso G.M. Osteocytes and WNT: the mechanical control of bone formation. J Dent Res 2010, 89:331-343.
28. Janda C.Y., Waghray D., Levin A.M., Thomas C., Garcia K.C. Structural basis of Wnt recognition by Frizzled. Science 2012, 337:59-64.
29. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002, 110:1419-1427.
30. Petit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699.
31. Anderson K.L., Smith K., Conners S.R., McKercher R.A., Maki R.A., Torbett B.E. Myeloid development is selectively disrupted in PU.1 null mice. Blood 1998, 91:3702-3710.
32. Mocsai A., Humphrey M.B., van Ziffle J.A., Hu Y., Burghardt A., Spusta S.C., et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcR-γ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 2004, 101:6158-6163.
33. Zhou L., Chong M.M., Littman D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30:646-655.
34. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000, 408:600-605.
35. Okamoto K., Takayanagi H. Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther 2011, 13:219-230.
36. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., et al. Up-regulation of TNF producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001, 98:13960-13965.
37. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alfa. J Clin Invest 2000, 106:1229-1327.
38. Lee S.K., Kadono Y., Okada F., Jacquin C., Koczon-Jareml B., Adams D.J., et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res 2006, 21:1704-1712.
39. Weitzmann M.N., Pacifici R. Estrogen regulation of immune cell bone interactions. Ann N Y Acad Sci 2006, 1068:256-274.
40. Goessl C., Katz L., Dougall W.C., Kostenuik P.J., Zoog H.B., Braun A., et al. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann N Y Acad Sci 2012, 1263:29-40.
41. Onal M., Xiong J., Chen X., Thostenson J.D., Almeida M., Manolagas S.C., et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 2012, 287:29851-29860.
42. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29:155-192.
43. Yoneda T., Ishimaru N., Arakaki R., Kobayashi M., Izawa T., Moriyama K., et al. Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis. Endocrinology 2004, 145:2384-2391.
44. Clowes J.A., Eghbali-Fatourechi G.Z., McCready L., Oursler M.J., Khosla S., Riggs B.L. Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. Osteoporos Int 2009, 20:761-769.
45. Binder N.B., Niederreiter B., Hoffmann O., Stange R., Pap T., Stuinig T.M., et al. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med 2009, 15:417-424.
46. Robinson L.J., Yaroslavskity B.B., Griswold R.D., Zadorozny E.V., Guo L., Tourkova I.L., et al. Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL regulated interaction of estrogen receptor alpha with BCAR1 and TRAF6. Exp Cell Res 2009, 315:1287-1301.
47. Pacifici R. Role of T cells in ovariectomy induced bone loss--revisited. J Bone Miner Res 2012, 27:231-239.
48. Takai H., Kanematsu M., Yano K., Tsuda E., Higashio K., Ikeda K., et al. Transforming growth factor-B stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998, 273:27091-27096.
49. Mödder U.I., Riggs B.L., Khosla S. The role of the immune system in the development of osteoporosis. Osteoimmunology 2011, 270-300. Academic Press, Elsevier Inc, London, cap. 9. J. Lorenzo, Y. Choi, M. Horowitz, H. Takayanagi (Eds.).
50. Gravallese E.M., Monach P.A. Rheumatoid synovitis and pannus. Rheumatology 2008, 841-865. Elsevier Ltd, London. M. Hochberg, J. Smolen, M. Weinblatt, M. Weisman (Eds.).
51. Deal C. Bone loss in RA: systemic, periarticular and focal. Curr Rheumatol Rep 2012, 14:231-237.
52. Goldring S., Schett G. The role of the immune system in the bone loss of inflammatory artritis. Osteoimmunology 2011, 301-324. Academic Press, Elsevier Inc, London, cap.10. J. Lorenzo, Y. Choi, M. Horowitz, H. Takayanagi (Eds.).
53. Okamoto K., Takayanagi H. Osteoclasts in arthritis and Th-17 cell development. Intern Immunopharmacol 2011, 11:543-548.
54. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012, 10:763-776.
55. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S. Defining the human T helper 17 cell phenotype. Trends Immunol 2012, 10:505-512.
56. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
57. Glatigny S., Blaton M.A., Mencher S.K., Mistou S., Lucas B., Fournier C., et al. Treatment of collagen-induced arthritis by Natura-alpha via regulation of Th-1/Th-17 responses. Eur J Immunol 2010, 40:460-469.
58. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
59. Takayanagi H. New developments in osteoimmunology. Nat Rev Rheumatol 2012, 8:684-689.
60. Genovese M.C., van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939.
61. Ivanov S., Lindén A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009, 30:95-103.
62. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012, 51(Suppl. 5):v3-v11.
63. Schett G., Gravallese E. Bone erosion in RA: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012, 8:656-664.
64. Lukas C., van der Heijde D., Fatenejad S., Landewé R. Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann Rheum Dis 2009, 69:851-855.
65. Møller Døhn U., Boonen A., Hetland M.L., Hansen M.S., Knudsen L.S., Hansen A., et al. Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1-year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 2009, 68:1585-1590.
66. Finzel S., Rech J., Schmidt S., Engelke K., Englbrecht M., Schett G. Interleukin 6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis 2013, 72:396-400.
67. Finzel S., Rech J., Schmidt S., Engelke K., Englbrecht M., Stach C., et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis 2011, 70:1587-1593.
68. Walsh N.C., Reinwald S., Manning C.A., Condon K.W., Iwata K., Burr D.B., et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009, 24:1572-1585.
69. Daoussis D., Andonopoulos A.P. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling?. Semin Arthritis Rheum 2011, 41:170-177.
70. Zhang W., Drake W.T. Potential role for therapies targeting DKK1, LRP5, and Serotonin in the treatment of osteoporosis. Curr Osteoporos Rep 2012, 10:93-100.
71. Luo J.L., Tan W., Ricono J.M., Korchynskyi O., Zhang M., Gonias S.L., et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 2007, 446:690-694.
72. Cao Y., Luo J.L., Karin M. IkB kinase a kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A 2007, 104:15852-15857.
73. Tan W., Zhang W., Strasner A., GrivennikovS, Cheng J.Q., Hoffman R.M., et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signaling. Nature 2011, 470:548-553.
74. Palafox M., Ferrer I., Pellegrini P., Vila S., Hernandez-Ortega S., Urruticoechea A., et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 2012, 72:2879-2888.
75. Beristain A.G., Narala S.R., di Grappa M.A., Khokha R. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci 2012, 125:943-955.
76. Green E.A., Choi Y., Flavell R.A. Pancreatic lymph node-derived CD4(+) CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002, 16:183-191.
77. Totsuka T., Kanai T., Nemoto Y., Tomita T., Okamoto R., Tsuchiya K., et al. RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. J Immunol 2009, 182:6079-6087.
78. Nakashima T., Hayashi M., Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endoc Metab 2012, 23:582-590.
79. Akiyama T., Shinzawa M., Akiyama N. RANKL-RANK interaction in immune regulatory systems. World J Orthop 2012, 3:142-150.
80. Ohigashi I., Nitta T., Lkhagvasuren E., Yasuda H., Takahama Y. Effects of RANKL on the thymic medulla. Eur J Immunol 2011, 41:1822-1827.
81. Taichman R.S., Emerson S.G. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med 1994, 179:1677-1682.
82. Sugiyama T., Nagasawa T. Bone marrow niches for hematopoietic stem cells and immune cells. Inflamm Allergy Drug Targets 2012, 11:201-206.
83. Guntur A.R., Rosen C.J., Naski M.C. N-cadherin adherens junctions mediate osteogenesis through PI3K signaling. Bone 2012, 50:54-62.
84. Mercier F.E., Ragu C., Scadden D.T. The bone marrow at the crossroad of blood and immunity. Nat Rev Immunol 2011, 12:49-60.
85. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stemm cell quiescence in the bone marrow niche. Cell 2004, 118:149-161.
86. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., et al. Osteoclast degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006, 12:657-664.
87. Miyamoto K., Yoshida S., Kawasumi M., Hashimoto K., Kimura T., Sato Y., et al. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med 2011, 208:2175-2181.
88. Geffroy-Luseau A., Jégo G., Bataille R., Campion L., Pellat-Deceunynck C. Osteoclasts support the survival of human plasma cells in vitro. Int Immunol 2008, 20:775-782.
89. Cain C.J., Rueda R., McLelland B., Collette N.M., Loots G.G., Manilay J.O. Absence of sclerostin adversely affects B-cell survival. J Bone Miner Res 2012, 7:1451-1461.
90. Buchwald Z.S., Kiesel J.R., DiPaolo R., Pagadala M.S., Aurora R. Osteoclast activated FoxP+ CD8+ T-cells supress bone resorption in vitro. Plos One 2012, 7:e38199. 10.1371/journal.pone.0038199.
91. Kiesel J.R., Buchwald Z.S., Aurora R. Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol 2009, 182:5477-5487.
92. Shrikant P.A., Rao R., Li Q., Kesterson J., Eppolito C., Mischo A., et al. Regulating functional cell fates in CD8 T cells. Immunol Res 2010, 46:12-22.
93. Cao X. Targeting osteoclast-osteoblast communication. Nat Med 2011, 17:1344-1346.
94. Takamatsu H., Kumanogoh A. Diverse roles for semaphoring-plexin signaling in the immune system. Trends Immunol 2012, 33:127-135.
95. Hayashi M., Nakashima T., Taniguchi M., Kodama T., Kumanogoh A., Takayanagi H. Osteoprotection by semaphorin 3A. Nature 2012, 485:69-74.